Business
Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team
- Industry veteran, Max Colao, appointed Chief Commercial Officer - - Recruited four seasoned executives with expertise across critical commercial functions
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":"\n- Industry veteran, Max Colao, appointed Chief Commercial Officer -\n\n\n- Recruited four seasoned executives with expertise across critical commercial functions -\n\n\n- Rapidly preparing for the potential commercialization of voclosporin during the first half of 2021 - \n\n VICTORIA, British Columbia--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the appointment of Max Colao to the newly created position of Chief Commercial Officer. In addition, Aurinia has recruited an experienced team of leaders across key commercial functions including sales, marketing, market access, and commercial operations.\n\n\n“This is a very exciting time at Aurinia, and we are laser-focused on executing on our strategy to prepare for a commercial launch next year. Assembling a world-class commercial leadership team in the months following the positive AURORA Phase 3 data is a testament to this commitment and voclosporin’s potential,” said Peter Greenleaf, President and Chief Executive Officer of Aurinia. “We believe the confirmatory AURORA data represented a potential breakthrough for people affected by lupus nephritis. The addition of Max’s invaluable experience, combined with the collective capabilities and expertise of our growing commercial organization, will be central to a successful market entry.”\n\n\nIn preparing for potential commercialization in 2021, Aurinia is building a distinguished team with proven experience in launching therapies for nephrology and autoimmune indications. The Company expects to file a new drug application (NDA) for voclosporin as a potential treatment for lupus nephritis (“LN”) in the second quarter of 2020. Joining the commercial organization along with Mr. Colao are:\n\n\n\nChris Hays, Vice President, Marketing;\n\n\nFran Lynch, Vice President, Sales;\n\n\nCara Felish, Vice President, Commercial Operations; and\n\n\nTim Hermes, Vice President, Market Access.\n\n\n\nThese hires follow the recently reported positive efficacy and safety results from the Company’s AURORA Phase 3 trial in the treatment of LN. Voclosporin was granted Fast Track designation by the FDA in 2016.\n\n\nMax Colao brings nearly 30 years of world-class commercial ope...